Side-by-side · Research reference
PinealonvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft12/36 cited
BFDA-ApprovedReviewed13/41 cited
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
Pinealon
PT-141
Primary target
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
Pinealon
PT-141
Standard dose
5–10 mg / day for 10 daysKhavinson 2014
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Once daily during cycle
PRN, max 8 doses / month
Lower / starter dose
2.5 mg / day
1 mg (off-label)
Evidence basis
Russian clinical trials + in vitroKhavinson 2014
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
10-day cycles, 1–2× per year
PRN; reassess if no benefit after 8 doses
Reconstitution
Bacteriostatic water
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
No specific time
≥45 min before sexual activity
04Side Effects & Safety
Parameter
Pinealon
PT-141
Injection site reaction
Mild irritation
Erythema, mild pain
Long-term safety
Limited Western data
—
Pregnancy / OB
Avoid
Contraindicated
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
Pinealon
- ·Pregnancy / breastfeeding
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
Pinealon
PT-141
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Injection site
SQ — abdomen preferred.
SQ — abdomen or thigh.
3. Timing
Daily during cycle, any time.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
29–31G, 4–8 mm insulin syringe.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation
PT-141
— no documented stacks